Review article: chronic viral infection in the anti‐tumour necrosis factor therapy era in inflammatory bowel disease

Alimentary Pharmacology and Therapeutics - Tập 31 Số 1 - Trang 20-34 - 2010
Matthew Shale1, Cynthia H. Seow2, Carla S. Coffin2, Gilaad G. Kaplan2, Remo Panaccione2, Subrata Ghosh2
1GI Section, Imperial College London, London, UK.
2Division of Gastroenterology, University of Calgary, AB, Canada

Tóm tắt

SummaryBackground  Anti‐Tumour necrosis factor (TNF) therapy is now well established in the treatment of inflammatory bowel disease and the risk of opportunistic infection is recognized. However, specific considerations regarding screening, detection, prevention and treatment of chronic viral infections in the context of anti‐TNF therapy in inflammatory bowel disease are not widely adopted in practice.Aim  To provide a detailed and comprehensive review of the relevance of chronic viral infections in the context of anti‐TNF therapy in inflammatory bowel disease.Methods  Literature search was conducted using Medline, Pubmed and Embase using the terms viral infection, hepatitis, herpes, CMV, EBV, HPV, anti‐TNF, infliximab, adalimumab, certolizumab pegol and etanercept. Hepatitis B and C and HIV had the largest literature associated and these have been summarized in Tables.Results  Particular risks are associated with the use of anti‐TNF drugs in patients with hepatitis B infection, in whom reactivation is common unless anti‐viral prophylaxis is used. Reactivation of herpes zoster is the most common viral problem associated with anti‐TNF treatment, and may be particularly severe. Primary varicella infection may present with atypical features in patients on anti‐TNF.Conclusion  Appreciation of risks of chronic viral disease associated with anti‐TNF therapy may permit early recognition, prophylaxis and treatment.

Từ khóa


Tài liệu tham khảo

10.1016/S0140-6736(02)08512-4

10.1053/j.gastro.2005.11.030

10.1056/NEJMoa011110

10.1097/00054725-200409000-00025

10.1002/art.10758

10.1002/hep.21513

10.1002/hep.20119

10.1016/j.cgh.2006.05.027

10.1136/gut.2005.070763

10.1002/hep.510290123

10.1016/S1074-7613(00)80295-2

10.1097/00054725-200409000-00035

10.1136/ard.62.7.686

10.1136/gut.2004.040675

10.3748/wjg.v12.i6.974

10.1007/s10620-005-1295-8

10.1136/ard.2004.031187

10.1002/art.21216

10.1007/s10067-006-0392-1

10.1002/ibd.20035

10.1002/ibd.20216

10.1111/j.1478-3231.2007.01665.x

10.1007/s00535-008-2165-x

10.1097/RHU.0b013e318181b89d

10.1093/rheumatology/kep003

Michel M, 2003, Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset Still’s disease, J Rheumatol, 30, 1624

10.1007/s10067-009-1149-4

Cansu DU, 2008, Short‐term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis, J Rheumatol, 35, 421

10.1007/s10067-008-0896-y

10.1136/ard.2004.028209

Oniankitan O, 2004, Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C, J Rheumatol, 31, 107

10.1093/rheumatology/kel123

10.1016/j.crohns.2009.02.010

10.1136/gut.2006.114660

10.1016/j.jaad.2007.08.030

10.1136/ard.2008.100834

10.1016/j.jhep.2008.07.014

10.1056/NEJM199907013410104

10.1002/ibd.20202

De Franchis R, 2003, EASL International Consensus Conference on Hepatitis B. Consensus Statement, J Hepatol, 39, S3

10.1111/j.1600-0676.1996.tb00768.x

10.1097/00007890-199611270-00007

10.1097/00042737-200102000-00016

10.1002/art.20702

10.1111/j.1572-0241.2003.07245.x

10.1016/j.jaad.2004.05.013

10.1007/s10067-006-0394-z

10.1093/rheumatology/kel191

10.1136/ard.62.11.1078

10.1002/art.21949

10.1016/j.jaad.2005.05.043

10.1016/j.jaad.2005.11.1035

10.1111/j.1365-4632.2008.03619.x

Cecchi R, 2006, Psoriasis and hepatitis C treated with anti‐TNF alpha therapy (etanercept), Dermatol Online J, 12, 4

Ferri C, 2008, Safety of anti‐tumor necrosis factor‐alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection, J Rheumatol, 35, 1944

Linardaki G, 2007, Effective etanercept treatment for psoriatic arthritis complicating concomitant human immunodeficiency virus and hepatitis C virus infection, J Rheumatol, 34, 1353

10.1016/j.autrev.2008.05.002

10.1111/j.1572-0241.2007.01131.x

10.1007/s10067-006-0412-1

10.1111/j.1468-3083.2008.02693.x

10.1016/j.jhep.2004.11.025

10.1111/j.1572-0241.2003.07539.x

10.1136/gut.42.6.856

Vauloup C, 2006, Effects of tumor necrosis factor antagonist treatment on hepatitis C‐related immunological abnormalities, Eur Cytokine Netw, 17, 290

10.1111/j.1365-2036.2008.03779.x

10.1016/S0006-291X(89)80213-X

10.4065/75.10.1093

10.1093/infdis/174.1.63

10.1097/00002030-200401230-00015

10.1136/gut.2006.101386

10.1016/j.jbspin.2006.05.012

10.1001/archinte.166.16.1783

10.1136/ard.2007.081513

10.1097/01.rhu.0000260411.75599.39

Gaylis N, 2003, Infliximab in the treatment of an HIV positive patient with Reiter’s syndrome, J Rheumatol, 30, 407

10.1111/j.0007-0963.2004.05885.x

10.1001/archderm.144.4.453

CDC, 2000, Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients: recommendations of CDC, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation, MMWR, 49, 1

10.7326/0003-4819-137-5_Part_2-200209031-00002

10.1038/323819a0

US Food and Drug Administration Center for Drug Evaluation and Research Website [Accessed July 28th 2008] (Available at:http://www.fda.gov/cder/aers/extract.htm)

Skripak JM, 2003, Disseminated herpes simplex (HSV) infection precipitating macrophage activation syndrome (MAS) in a child with systemic juvenile idiopathic arthritis (SJIA) undergoing therapy with infliximab [abstract], Pediatr Rheumatol Online J, 1, S58

10.1007/s00134-003-1867-z

10.1016/j.jbspin.2007.10.011

10.1001/jama.2009.146

Becart S, 2008, Recurrent varicella in an adult psoriasis patient treated with etanercept, Dermatology, 217, 260, 10.1159/000149311

10.1136/pmj.2003.014373

10.1016/j.jaad.2008.10.002

10.1111/j.1468-3083.2006.01984.x

10.1111/j.1365-4632.2006.02779.x

10.1111/j.1572-0241.2004.41389_7.x

Vonkeman H, 2004, Disseminated primary varicella infection during infliximab treatment, J Rheumatol, 31, 2517

10.3748/wjg.14.2912

10.1086/500262

10.1086/425123

10.1086/428672

10.1097/00042737-200212000-00018

10.1002/ibd.20131

10.1093/rheumatology/keh696

10.1016/j.jcv.2008.06.002

2004, Epstein–Barr virus and lymphoproliferative disorders after transplantation, Am J Transplant, 4, 59

2004, Human papillomavirus infection, Am J Transplant, 4, 95

Siegel CA, 2008, Risk of lymphoma associated with anti‐TNF agents for the treatment of Crohn’s disease: A meta‐analysis, Gastroenterology, 134, A144

10.1016/j.cgh.2006.03.002

10.1002/art.10679

10.1002/art.22579

10.3109/s10165-008-0053-0

10.1007/s00296-007-0467-6

10.1097/00054725-200403000-00004

10.1002/art.22783

10.1097/00005176-200305000-00007

10.1111/j.1572-0241.2007.01582.x

10.1053/j.gastro.2008.10.021

Fireman B, 2008, Screening differences and risk of cervical cancer in inflammatory bowel disease, Aliment Pharmacol Ther, 28, 598, 10.1111/j.1365-2036.2008.03766.x

10.1136/pgmj.2003.009332

10.1159/000117709

10.1136/ard.62.7.684

10.1128/CMR.16.3.357-364.2003

10.1097/00054725-200409000-00028

10.1111/j.1572-0241.2006.00646.x

Kaine JL, 2007, Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab, J Rheumatol, 34, 272

10.1053/j.gastro.2008.01.012

Thông tin
Thông tin xuất bản

Alimentary Pharmacology and Therapeutics

Tập 31 Số 1

20-34

Thông tin tác giả